A combination of the personalized cancer vaccine intismeran autogene and Merck's Keytruda just barely cleared analysts’ ...
After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted ...
Completion of light dose-escalation Part A of Phase 1 study identifies regimen for further evaluation in Part B, supporting ...
MESA, AZ / ACCESS Newswire / October 23, 2026 / Medical Care Technologies Inc. (OTCID:MDCE) today announced that it is ...
Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today ...
AbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late ...
Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay ...
October 23, 2026) - Global Hemp Group Inc. (CSE: GHG) (FSE: GHG0) (OTC PINK: GBHPF) ("GHG" or the "Company") is pleased to ...
(Biokin) reported positive results from a prespecified interim analysis of the randomized Phase 3 PANKU-Breast01 study ...
U.S. Patent No. 12,734,179 B2, titled Progesterone formulation to trigger ovulation and provide luteal phase support, was ...
Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026
Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting ...
Following the withdrawal of billions of dollars in investments from Boehringer Ingelheim and Eli Lilly, German lawmakers have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results